<DOC>
	<DOCNO>NCT01358162</DOCNO>
	<brief_summary>Healthy male female volunteer give SQ109 300mg daily 14 day assess safety tolerability pharmacokinetics .</brief_summary>
	<brief_title>Phase IC Study Safety PK SQ109 300mg Daily</brief_title>
	<detailed_description>This Phase 1C randomize , placebo control , double-blinded , in-patient trial single oral dose 300 mg SQ109 give daily 14 consecutive day evaluate safety , tolerability pharmacokinetics SQ109 normal healthy male female subject 18-45 year age . Each subject receive 300 mg SQ109 placebo .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subject must 18 45 year age ( inclusive ) . Subject must healthy male female volunteer ( i.e. , hematology , coagulation , clinical chemistry urinalysis test must within studydefined range ( See Appendix B ) . Clinical test must perform within 28 day receive first dose study drug . Body Mass Index ( BMI ) must 18 30 kg/m2 inclusive . Subject must Tuberculin Skin Test/Purified Protein Derivative ( TST/PPD ) negative ( within previous 1 year ) Screening . The TST/PPD may omit subject present write evidence negative test previous 12 month . Subject must able give voluntary write informed consent study related procedure perform . If female , childbearing potential agrees avoid become pregnant day screen entire participation trial ( Day 28 ) use one follow acceptable method birth control plus recommend use barrier method ( condom ) male partner ( even vasectomize ) : 1. intrauterine contraceptive device ; 2. diaphragm combination contraceptive jelly , cream , foam ; 3. spermicide ; 4. abstinence . Nonchildbearing potential define postmenopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy status hysterectomy . Hormonal contraceptives type form ( include oral , transdermal , vaginal depot preparation ) allow study . All female subject childbearing potential must negative serum pregnancy test screening within 24 hour first dose study product . Male subject must agree use acceptable barrier method birth control ( abstinence use condom spermicide ) screening Study Day 28 advice recommend use additional birth control ( criterion 6 ) female sex partner throughout study . Subject agree donate blood study 30 day Study Day 28 . Subject agree comply study requirement , include clinic house rule . A history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , opinion Principal Investigator ( PI ) , would jeopardize safety subject impact validity study result . Subject abnormal diet 4 week precede study . Abnormal diet define diet subject significant change eat habit ( e.g. , liquid diet ) unbalance diet ( e.g. , protein , high fat , low carbohydrate , etc. ) . Subject receive investigational drug clinical trial within 30 day prior study initiation . Subject use OTC medication , include vitamin herbal supplement , within 7 day prior Day 1 study , unless opinion PI , substance would likely impact conduct study , include PK SQ109 . Subject use prescription medication within 14 day prior Day 1 study , use hormonal preparation contain sex hormone within 30 day prior Day 1 study . Subject current medical condition require treatment medication , either prescription OTC . Subject treat know CYP450 enzyme alter drug azoles , antifungal , barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior Day 1 study . Subject positive blood screen HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody and/or positive history alcohol abuse dependence and/or positive serum ethanol positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine metabolite , marijuana , opiates , phencyclidine ( PCP ) ) . Subject baseline QTcF interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) ( define Section 9.1.3 ) family history prolong QTcF syndrome premature cardiac death . Subject Wolf Parkinson White Syndrome ( WPW ) family history WPW history supraventricular tachycardia syncope . Subject live person active TB travel area endemic TB within past 12 month . Subject abnormal result Ishihara color test , funduscopic exam , current optic neuritis know retinal disease . Subject uncontrolled intercurrent illness ( i.e. , active infection ) fever ( oral temperature &gt; /=100 degrees F &gt; /= 37.7 degree C ) . Subject major surgery within 4 week study entry . Women pregnant breastfeeding . Subject donate blood within past 30 day prior Day 1 study . Subject allergy ethambutol relate compound . Subject employee family member employee Sequella , Quintiles , DynPort Vaccine Company LLC ( DVC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Tuberculosis</keyword>
</DOC>